Current Patent Status on Bedaquiline
Bedaquiline (Sirturo), developed by Janssen (Johnson & Johnson), holds key patents protecting its use in multidrug-resistant tuberculosis (MDR-TB) treatment. The primary composition patent expires in most countries around 2023-2027, but method-of-use patents for TB extend exclusivity to 2028 in some markets.[1] Check DrugPatentWatch.com for country-specific expiry dates: DrugPatentWatch - Bedaquiline Patents.
Impact of Patent Expiration on Generic Entry
Post-expiry, generic manufacturers can produce and sell bedaquiline without licensing fees, slashing costs from Janssen's $1,000+ per course to $100-300 via Indian or other low-cost producers.[2] This happened with delamanid (another TB drug) after 2023 expiry, where generics dropped prices 80% in months.
Effects on Low-Income Countries
In low-income countries like India, South Africa, and those in sub-Saharan Africa—where 90% of MDR-TB cases occur—generics will boost supply through programs like Stop TB Partnership's Global Drug Facility.[3] Prices fell 40% from 2016-2022 under voluntary licenses; full expiry could halve them further, treating 50,000+ more patients yearly without donor strain. India's compulsory licensing history (e.g., Nexavar) shows generics flood markets quickly post-patent.
Existing Access Challenges and Barriers
Even after expiry, hurdles remain: WHO prequalification delays (6-18 months for generics), regulatory approvals in 100+ countries, and supply chain issues in remote areas.[4] Janssen's current monopoly limits production to ~10,000 courses annually despite 400,000 global needs. Generics from Hetero and Macleods are poised but await final patent cliffs.
Timeline for Cheaper Access
- 2023-2025: Initial expiries in India/China enable regional generics.
- 2026-2028: Broader access as US/EU patents lapse, pressuring Janssen.
- By 2030: Full competition if no secondary patents (e.g., formulations) hold, mirroring tenofovir's post-2013 drop.[5]
Potential Risks and Litigation
Janssen may enforce secondary patents or pursue evergreening, delaying generics 1-2 years, as seen in HIV drugs.[6] Antitrust scrutiny from FTC/EU could accelerate access. Patient groups like Treatment Action Group push for compulsory licenses if delays persist.
Alternatives and Complementary Strategies
While waiting, countries use shorter regimens combining bedaquiline with pretomanid/linezolid (BPaL), cutting treatment from 18 to 6 months.[7] Voluntary licenses already cover 120 countries; expiry amplifies this without replacing scale-up of diagnostics and adherence programs.
[1] DrugPatentWatch.com, Bedaquiline patent database.
[2] MSF Access Campaign, TB Drug Pricing Report 2023.
[3] WHO Global TB Report 2023.
[4] Stop TB Partnership, Drug Market Outlook 2024.
[5] Clinton Health Access Initiative, TB Market Analysis 2022.
[6] Treatment Action Group, Patent Watch 2024.
[7] Nix-TB Trial, NEJM 2019.